AG真人官方

Moleculin Biotech (MBRX) has announced a significant public offering totaling $5.9 million in gross proceeds, with potential for an additional $17.8 million if all warrants are exercised. The offering, which closed on June 23, 2025, includes:

• 9,972,026 shares of common stock
• 6,107,974 pre-funded warrants at $0.001 exercise price
• 48,240,000 Series E warrants at $0.37 initial exercise price

Notable aspects include insider participation, with CEO Walter Klemp and CFO Jonathan Foster purchasing 1,027,026 shares and 3,081,078 warrants. Roth Capital Partners served as placement agent, receiving a 7% fee. The proceeds will fund clinical development of Annamycin and two other drug portfolios, preclinical studies, and working capital.

The offering includes significant stockholder approval requirements and anti-dilution provisions, with warrant exercise prices subject to potential downward adjustments (floor price $0.12). The company has agreed to a 60-day restriction on new share issuances following stockholder approvals.

Jonathan P. Foster, Chief Financial Officer of Moleculin Biotech (MBRX), reported multiple securities transactions on June 20-23, 2025:

• Acquired 2,711 shares from RSUs and had 661 shares withheld for taxes on June 20
• Acquired 4,328 shares from RSUs and had 1,054 shares withheld for taxes on June 22
• Purchased 270,270 common shares at $0.37 per share in a public offering on June 23
• Acquired Series E warrants to purchase 810,810 shares at $0.37/share, exercisable upon stockholder approval with 5-year expiration

Following these transactions, Foster directly owns 287,587 common shares and 1,038,320 derivative securities. The RSUs were granted in 2022 (10,846 units) and 2023 (17,313 units), vesting in four annual installments. This significant insider purchase demonstrates management's confidence in the company's prospects.

Walter V. Klemp, CEO, President and Director of Moleculin Biotech (MBRX), reported multiple insider transactions on June 20-23, 2025:

• Acquired 3,750 shares from RSU vesting on June 20, with 914 shares withheld for taxes
• Acquired 8,990 shares from RSU vesting on June 22, with 2,190 shares withheld for taxes
• Purchased 675,675 common shares at $0.37 per share in a public offering on June 23
• Acquired Series E warrants to purchase 2,027,025 additional shares at $0.37/share

Following these transactions, Klemp directly owns 743,607 common shares and 2,409,481 derivative securities. The Series E warrants will be exercisable upon stockholder approval and expire 5 years after approval. These transactions demonstrate significant insider investment in the company, particularly through participation in the public offering.

Donald H. Picker, Chief Science Officer of Moleculin Biotech (MBRX), reported multiple transactions involving restricted stock units (RSUs) and common stock:

• On June 20, 2025, converted 1,078 RSUs to common stock and had 263 shares withheld for tax purposes at $0.267 per share, resulting in 8,816 directly owned shares
• On June 22, 2025, converted 1,766 RSUs to common stock and had 430 shares withheld for tax purposes at $0.267 per share, resulting in 10,152 directly owned shares

These transactions stem from two RSU grants: 4,312 units granted on June 20, 2022, and 7,063 units granted on June 22, 2023, both vesting in four equal annual installments. Following these transactions, Picker maintains direct ownership of 104,258 RSUs.

Moleculin Biotech (MBRX) has announced a public offering of securities including 9,972,026 shares of common stock and Series E warrants to purchase up to 29,916,078 shares, along with 6,107,974 pre-funded warrants and accompanying Series E warrants.

Key offering details:

• Combined purchase price: $0.37 per share and accompanying warrant
• Series E warrants exercise price: $0.37 per share, expires 5 years from stockholder approval
• Pre-funded warrants exercise price: $0.001 per share
• Total expected proceeds: $5.95 million before expenses
• Placement agent: Roth Capital Partners, receiving 7% fee

The company is conducting a Phase 3 trial of Annamycin for relapsed/refractory acute myeloid leukemia, with interim data expected by end of 2025. Management, including CEO Walter Klemp and CFO Jonathan Foster, will participate in the offering by purchasing 1,027,026 shares with warrants. The offering closes around June 23, 2025.